MCID: PLL012
MIFTS: 44

Pollen Allergy

Categories: Immune diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Pollen Allergy

MalaCards integrated aliases for Pollen Allergy:

Name: Pollen Allergy 11 14 75
Hay Fever 71

Classifications:



External Ids:

Disease Ontology 11 DOID:0060497
UMLS 71 C0018621

Summaries for Pollen Allergy

Disease Ontology: 11 A respiratory allergy triggered by pollen.

MalaCards based summary: Pollen Allergy, also known as hay fever, is related to timothy grass allergy and allergic rhinitis, and has symptoms including tinnitus, rhinorrhea and snoring. An important gene associated with Pollen Allergy is PDCL (Phosducin Like), and among its related pathways/superpathways are Akt Signaling and T-cell activation SARS-CoV-2. The drugs Histamine and Fluticasone have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and b cells, and related phenotype is homeostasis/metabolism.

Wikipedia: 75 Allergic rhinitis, of which the seasonal type is called hay fever, is a type of inflammation in the nose... more...

Related Diseases for Pollen Allergy

Diseases related to Pollen Allergy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 442)
# Related Disease Score Top Affiliating Genes
1 timothy grass allergy 32.2 PEDS1 PDCL PDC
2 allergic rhinitis 32.1 IL5 IL4 IL13 IL10
3 rhinitis 31.0 IL5 IL4 IL13 IL10 ICOSLG
4 chronic rhinitis 30.7 PTGDR2 PEDS1 PDCL IL5 IL4 IL13
5 ige responsiveness, atopic 30.5 IL5 IL4 IL13 IL10
6 eosinophilic gastroenteritis 30.5 IL5 IL4 IL13
7 allergic asthma 30.4 IL5 IL4 IL13 IL10 CCR6
8 conjunctivitis 30.3 PTGDR2 IL5 IL4 IL13 IL10
9 apple allergy 30.3 SCP2 PEDS1 PDCL PDC GHITM
10 dermatitis 30.2 IL5 IL4 IL13 IL10 CCR6
11 celery allergy 30.2 SCP2 PEDS1 PDCL GHITM
12 esophagitis 30.2 IL5 IL4 IL13 IL10
13 allergic disease 30.1 IL5 IL4 IL13 IL10 ICOSLG CD4
14 exercise-induced bronchoconstriction 30.1 IL5 IL4 IL13
15 henoch-schoenlein purpura 30.0 ICOSLG CD4 CCR6
16 toxoplasmosis 29.9 IL5 IL4 IL10
17 thunderstorm triggered asthma 29.9 PEDS1 PDCL PDC IL5 IL4 IL13
18 bronchitis 29.8 IL5 IL4 IL13 IL10
19 hypereosinophilic syndrome 29.8 IL5 IL4 IL13 IL10
20 esophagitis, eosinophilic, 1 29.8 PTGDR2 IL5 IL4 IL13 ICOSLG CCR6
21 asthma 29.8 PTGDR2 IL5 IL4 IL13 IL10 ICOSLG
22 ulcerative colitis 29.6 IL5 IL4 IL13 IL10 CCR6
23 urticaria 29.3 IL5 IL4 IL13 IL10 ENPP3 CD63
24 peach allergy 29.3 SCP2 PEDS1 PDCL PDC ENPP3 CD63
25 food allergy 29.3 SCP2 PEDS1 PDCL IL5 IL4 IL13
26 childhood-onset asthma 29.2 IL5 IL4 IL13 IL10 CD4 CCR6
27 respiratory failure 29.2 IL5 IL4 IL13 IL10 CD4 CCR6
28 allergic conjunctivitis 29.0 IL5 IL4 IL13 IL10 ICOSLG CD4
29 allergic contact dermatitis 29.0 IL5 IL4 IL13 IL10 ICOSLG CD4
30 colitis 29.0 IL5 IL4 IL13 IL10 ICOSLG CD4
31 exanthem 29.0 IL4 IL10 ICOSLG CD4 CCR6 ALK
32 respiratory allergy 29.0 PTGDR2 PEDS1 PDCL PDC IL5 IL4
33 dermatitis, atopic 28.9 PTGDR2 PEDS1 IL5 IL4 IL13 IL10
34 contact dermatitis 28.5 PTGDR2 PEDS1 IL5 IL4 IL13 IL10
35 nut allergy 28.4 SCP2 PEDS1 PDCL IL5 IL4 IL13
36 peanut allergy 27.6 SCP2 PEDS1 PDCL IL5 IL4 IL13
37 fruit allergy 27.3 SCP2 PTGDR2 PEDS1 PDCL PDC IL5
38 crab allergy 10.3 PEDS1 ENPP3
39 aztreonam allergy 10.3 IL5 IL13
40 nickel allergic contact dermatitis 10.3 IL5 IL13
41 respiratory syncytial virus infectious disease 10.3 IL5 IL13
42 enterobiasis 10.3 IL5 IL4
43 loeffler syndrome 10.2 IL5 IL13
44 ceftriaxone allergy 10.2 PEDS1 IL10
45 cercarial dermatitis 10.2 IL5 IL4
46 contact blepharoconjunctivitis 10.2 PTGDR2 IL5
47 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.2
48 vegetable allergy 10.2 SCP2 PEDS1 PDCL GHITM
49 orange allergy 10.2 SCP2 PDCL PDC IL5
50 aspirin-induced respiratory disease 10.2 IL5 IL13

Graphical network of the top 20 diseases related to Pollen Allergy:



Diseases related to Pollen Allergy

Symptoms & Phenotypes for Pollen Allergy

UMLS symptoms related to Pollen Allergy:


tinnitus; rhinorrhea; snoring; sore throat; coughing; vertigo/dizziness; equilibration disorder

GenomeRNAi Phenotypes related to Pollen Allergy according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.19 ALK CCR6 CD4 CD63 COPS7A ENPP3
2 no effect GR00402-S-2 10.19 ALK CCR6 CD4 CD63 COPS7A ENPP3

MGI Mouse Phenotypes related to Pollen Allergy:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.5 ALK CCR6 CD4 CD63 COPS7A ICOSLG

Drugs & Therapeutics for Pollen Allergy

Drugs for Pollen Allergy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 66)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 4 51-45-6 774
2
Fluticasone Approved, Experimental Phase 4 90566-53-3 4659387 5311101
3
Cetirizine Approved Phase 4 83881-51-0 2678
4
Loratadine Approved, Investigational Phase 4 79794-75-5 3957
5
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
6
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
7
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
8
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
9
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
10
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
11 Respiratory System Agents Phase 4
12
Histamine phosphate Phase 4 51-74-1 134614
13 Anti-Allergic Agents Phase 4
14 Bronchodilator Agents Phase 4
15 Anti-Asthmatic Agents Phase 4
16 Xhance Phase 4
17 Dermatologic Agents Phase 4
18 Histamine H1 Antagonists Phase 4
19 Histamine Antagonists Phase 4
20 Neurotransmitter Agents Phase 4
21 Histamine H1 Antagonists, Non-Sedating Phase 4
22 Antineoplastic Agents, Hormonal Phase 4
23 Neuroprotective Agents Phase 4
24 Hormones Phase 4
25 Hormone Antagonists Phase 4
26 Antiemetics Phase 4
27 glucocorticoids Phase 4
28 Pharmaceutical Solutions Phase 4
29 Anti-Inflammatory Agents Phase 4
30
Methylprednisolone Acetate Phase 4 584547
31 Gastrointestinal Agents Phase 4
32 Protective Agents Phase 4
33
Sorbitol Approved, Investigational Phase 3 69-65-8, 50-70-4 453 6251 5780
34
Ciclesonide Approved, Investigational Phase 3 126544-47-6, 141845-82-1 444033 6918155
35
Aluminum hydroxide Approved, Investigational Phase 3 21645-51-2
36
Glutaral Experimental Phase 3 111-30-8 3485
37
Salmeterol Xinafoate Phase 3 94749-08-3
38
Beclomethasone Phase 3 2308 20469
39 Vaccines Phase 3
40
Omalizumab Approved, Investigational Phase 2 242138-07-4
41
Coal tar Approved Phase 2 8007-45-2
42
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 2 133585-56-5, 60-18-4, 556-02-5 1153 6057
43 Immunoglobulins, Intravenous Phase 2
44 Immunoglobulin E Phase 2
45 Acidophilus Phase 1, Phase 2
46 Bifidobacterium Phase 1, Phase 2
47 Immunoglobulins Phase 2
48 Antibodies Phase 2
49 Immunologic Factors Phase 2
50 Antibodies, Monoclonal Phase 2

Interventional clinical trials:

(show top 50) (show all 74)
# Name Status NCT ID Phase Drugs
1 A Placebo Controlled, Double-Blind, Randomised Study to Assess Efficacy of Sublingual Immunotherapy in Patients With Grass Pollen Allergy Through Assessment of Its Immunological Effects on the Mucosal Tissue of the Nose. Completed NCT00150514 Phase 4 Oralgen
2 Comparison of the Effect of Fluticasone Furoate Nasal Spray Versus Placebo on Allergic Mediators in the Tears of Subjects With Tree or Grass Pollen Allergy Completed NCT00891436 Phase 4 Fluticasone furoate nasal spray;Placebo nasal spray
3 Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Zyrtec® (Cetirizine HCl) Syrup vs. Claritin® (Loratadine) Syrup vs. Placebo in Treatment of Children With Seasonal Allergic Rhinitis (SAR) Completed NCT02932774 Phase 4 Cetirizine;Loratadine
4 Is the Effect of Systemic Steroids Treating Pollen Induced Allergic Rhinitis Mainly Due to a Placebo Effect Active, not recruiting NCT04622917 Phase 4 MethylPREDNISolone 40 Mg/mL Injectable Suspension;NaCl 9 MG/ML Injectable Solution
5 A Multicentre, International, Randomised, Double-blind, Placebo-controlled Study to Demonstrate the Clinical Efficacy and Safety of Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis Unknown status NCT03724240 Phase 3
6 A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment Initiated in the Grass Pollen Season in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis Completed NCT00773240 Phase 3 Grazax;placebo
7 A Multicentre, Placebo-controlled, Double-blind Study to Evaluate Efficacy and Safety of a Perennial Sublingual Specific Immunotherapy With a Liquid Formulation of an Extract of a Six Grass Pollen-mixture in Patients With Clinically Relevant Grass Pollen Sensitivity. Completed NCT00264459 Phase 3
8 A Multicentre Randomised Placebo-controlled Double-blind Clinical Trial for Evaluation of Safety and Efficacy of Immunotherapy With an Aluminium Hydroxide-adsorbed Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen, Bet v 1 Completed NCT00309062 Phase 3
9 A Multicentre Randomised Placebo-controlled Double-blind Clinical Trial for Evaluation of Safety and Efficacy of Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Allergoid Preparation of Birch Pollen Allergens Completed NCT00263627 Phase 3
10 A Multicentre, Placebo Controlled, Double-Blind Study for Evaluation of Safety and Efficacy of Preseasonal Specific Immunotherapy With an Allergoid Preparation of an Extract of a 6 Grass Pollen Mixture in Patients With Clinically Relevant Grass Pollen Sensitivity Completed NCT00263601 Phase 3
11 Comparison of the Efficacy and the Safety of Different Schedules of Administration of Sub-lingual Immunotherapy in Patients With Ragweed Pollinosis: a Phase III Randomized and Controlled Clinical Study Completed NCT01500642 Phase 3
12 A Nasally Applied Cellulose Powder in Seasonal Allergic Rhinitis in Adults With Grass Pollen Allergy: A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group Study Completed NCT03039816 Phase 2, Phase 3
13 A Randomized, Double-blind, Placebo-controlled, Parallel-group, Clinical Trial Designed to Assess the Safety of Ciclesonide, Applied as a Nasal Spray at Three Dose Levels, 200µg, 100µg or 25µg Once Daily for Six Weeks, in the Treatment of Perennial Allergic Rhinitis (PAR) in Pediatric Patients 2-5 Years of Age. Completed NCT00658918 Phase 3 Ciclesonide nasal;Placebo
14 A Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 3 Clinical Trial to Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray (200µg Once Daily) in the Treatment of Seasonal Allergic Rhinitis (SAR) in Patients 12 Years and Older Completed NCT00659841 Phase 3 Ciclesonide;Placebo
15 A Randomized, Double-blind, Placebo-controlled, Parallel-group Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray (200 mcg, Once Daily), in the Treatment of Seasonal Allergic Rhinitis (SAR) in Patients 18 Years and Older Completed NCT00384475 Phase 3 Ciclesonide Nasal Spray
16 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray (200 mg, Once Daily), in the Treatment of Seasonal Allergic Rhinitis (SAR) in Patients 18 Years and Older Completed NCT00659594 Phase 3 Ciclesonide;Placebo
17 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Using the Environmental Exposure Unit (EEU) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray (200 mg, Once Daily), in the Treatment of Seasonal Allergic Rhinitis (SAR) in Patients 18 Years and Older Completed NCT00659503 Phase 3 Ciclesonide;Placebo
18 A Multicenter, International, Randomised, Double-blind, Placebo Controlled Study to Demonstrate the Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis Completed NCT02560948 Phase 3
19 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Trial Designed to Assess the Efficacy and Safety of Ciclesonide Applied as a Nasal Spray at Three Dose Levels (200 Mcg, 100 Mcg, or 25 Mcg, Once Daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Patients 6-11 Years of Age Completed NCT00163514 Phase 3 Ciclesonide
20 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Clinical Trial Designed to Assess the Safety and Tolerability of Ciclesonide (200 mcg Once Daily), Applied as a Nasal Spray for Twelve Weeks, in the Treatment of Perennial Allergic Rhinitis (PAR) in Pediatric Patients 2-5 Years of Age Completed NCT00261287 Phase 3 Ciclesonide
21 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Clinical Trial Designed to Assess the Safety and Efficacy of Ciclesonide (200mcg and 100mcg, Once Daily) Applied as a Nasal Spray for Two Weeks in the Treatment of Seasonal Allergic Rhinitis (SAR) in Patients 6 to 11 Years of Age Completed NCT00305487 Phase 3 Ciclesonide nasal spray
22 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Trial to Assess the Long Term Safety of Ciclesonide, Applied as a Nasal Spray (200 Mcg, Once Daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Patients 12 Years and Older Completed NCT00163501 Phase 3 Ciclesonide
23 Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Fluticasone Propionate/Salmeterol (FP/SAL) in Patients (18-60 Years) With Perennial Allergic Rhinitis (PAR) Completed NCT00163488 Phase 3 Ciclesonide
24 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate Hydrofluoroalkane (BDP HFA) Nasal Aerosol in Subjects 12 Years of Age and Older With SAR Completed NCT01024608 Phase 3 Beclomethasone dipropionate;Placebo Nasal Aerosol
25 Prospective, Randomized, Placebo-controlled, Multi-center Trial Comparing the Efficacy and Safety of Subcutaneous Immunotherapy With a Mixture of Grasses and Mites at Adequate Doses Versus Monotherapy, for the Treatment of Allergy Recruiting NCT04874714 Phase 3
26 Two Center Evaluation of the Safety and Efficacy of Topical Nasal rEV131 Versus rEV131 Vehicle (Placebo)in the Prevention of the Signs and Symptoms of Allergic Rhinitis Induced by Nasal Allergen Challenge Unknown status NCT00247520 Phase 1, Phase 2 topical nasal rEV131
27 A Randomized Study to Evaluate a Novel Method of Specific Allergen Immunotherapy in Grass and/or Tree Pollen Allergic Subjects by Intralymphatic Allergen Administration Completed NCT00470457 Phase 2
28 SUBLIVAC® Birch Prospective, Randomized, Open, Blinded Endpoint (PROBE) Study Completed NCT00932607 Phase 2 sublingual immunotherapy
29 A Dose-response Evaluation of ALK Tree AIT Completed NCT01675791 Phase 2
30 A Bicentre Open Label Randomised Pilot Study for Proof of Safety and Efficacy of Immunotherapy With an Aluminium Hydroxide-adsorbed Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen Bet v 1-FV Versus a Depot Extract of Natural Birch Allergen Completed NCT00266526 Phase 2
31 Safety and Dose Finding Study Based on the Effects of Three Subcutaneous Injections of BM32, a Recombinant Hypoallergenic Grass Pollen Vaccine, on Responses to Allergen Challenge by Skin Testing and in the Vienna Challenge Chamber (VCC) as Well as Immunological Response in Subjects Know to Suffer From Grass-pollen Induced Allergic Rhinitis Completed NCT01445002 Phase 2
32 Sublingual Immunotherapy of Birch Pollen Associated Apple Allergy Completed NCT01449786 Phase 2 rMal d 1;rBet v 1
33 Phase IIb Study on the Safety and Efficacy of BM32, a Recombinant Hypoallergenic Vaccine for Immunotherapy of Grass Pollen Allergy Completed NCT01538979 Phase 2
34 Clinical Efficacy, Immunogenicity, Clinical Tolerability and Assessment of Safety of gpASIT+TM Administered Orally, According to Two Administration Schedules, for the Prophylaxis of Seasonal Grass Pollen Rhinoconjunctivitis Completed NCT01308021 Phase 2
35 Double Blind, Placebo-controlled, Dose Finding, Prospective, Multicenter Clinical Trial for the Treatment of Rhinitis/Rhinoconjunctivitis Against Grass Pollen Allergy Completed NCT02654223 Phase 2
36 A Multicentre Open Label Safety Study of a Sublingual Specific Immunotherapy With a Solution of Birch Pollen Allergen Extract in Patients With Clinically Relevant Birch Pollen Allergy Completed NCT00818181 Phase 2 Biological: AL0206st
37 Probiotic Intervention for Children With Birch Pollen Allergy Completed NCT00746226 Phase 1, Phase 2
38 Explorative Analysis of the Immunomodulatory Capacities of Apathogenic Escherichia Coli Nissle 1917 in Patients With Rhinoconjunctivitis Due to Grass Pollen Allergy Completed NCT01013259 Phase 2 Mutaflor;Placebo
39 Safety, Immunogenicity and Clinical Efficacy of an Allergen Vaccine (CYT005-AllQbG10) in Subjects With Seasonal Rhinoconjunctivitis Due to Grass-Pollen Allergy Completed NCT00293904 Phase 1, Phase 2
40 Safety, Clinical Tolerability and Immunogenicity of Increasing Doses of gpASIT+TM Administered Subcutaneously to Hay Fever Patients Completed NCT02156791 Phase 2
41 Safety, Clinical Tolerability and Immunogenicity of gpASIT+TM Administered Subcutaneously to Hay Fever Patients Either Alone or in Presence of DnaK Immunoregulating Adjuvant Completed NCT01506375 Phase 2
42 A Randomized, Double-blind, Placebo-controlled, 5-arm Parallel Study to Evaluate the Pharmacokinetics/ Pharmacodynamics and Steady State Efficacy of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo Given Orally in the Treatment of the Symptoms of Seasonal Allergic Rhinitis in an Environmental Exposure Chamber (EEC) Mode Completed NCT00574210 Phase 2 Bilastine;Placebo
43 A Multi-Center Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo Given Orally in The Treatment of the Symptoms of Seasonal Allergic Rhino-Conjunctivitis With Allergy to Mountain Cedar Pollen Completed NCT00574379 Phase 2 Bilastine;Placebo
44 Efficacy and Safety Evaluation of Allergen Immunotherapy Co-Administered With Omalizumab, an Anti-IgE Monoclonal Antibody (ITN019AD) Completed NCT00078195 Phase 2
45 Grass Pollen Sublingual Tablet Immunotherapy Plus Dupilumab for Induction of Tolerance in Adults With Moderate to Severe Seasonal Allergic Rhinitis (ITN084AD) Recruiting NCT04502966 Phase 2 Dupixent® Placebo;Grazax® Placebo
46 Safety and Efficacy of Low-dose IL-2 in Birch Pollen Allergy Recruiting NCT03776643 Phase 2 ILT-101 ld-(IL2)
47 A Double Blind Study to Investigate the Clinical Efficacy and Safety of TreeMATAMPL (Allergy Therapeutics, (UK) Ltd.), TreeMATA (Allergy Therapeutics, (UK) Ltd.) and Placebo in Patients With Seasonal Allergic Rhinitis Due to Birch Pollen Allergy, in an Environmental Exposure Chamber (EEC) Model When Exposed to Birch Pollen and Oak Pollen Terminated NCT00387478 Phase 2
48 A Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety and Tolerability of Subcutaneous Immunotherapy With DM-101 in Adults With Birch Pollen Allergy Completed NCT04266028 Phase 1
49 A Randomized, Double-blind, Placebo-controlled Study to Determine the Safety, Tolerability and Immunological Effects of BM41 Compared to Placebo and to Treatment With Standard Subcutaneous Immunotherapy (as Open Comparator) in Patients With Moderate to Severe Allergic Rhinitis/ Rhino-conjunctivitis Caused by Birch Pollen Completed NCT04912076 Phase 1 BM41;ALK Alutard SQ Betula verrucosa
50 Comparison of the Influence of Different Skin Conditions on the Allergic Skin Reactivity to Epicutaneous Allergen Exposure Completed NCT01628484 Phase 1

Search NIH Clinical Center for Pollen Allergy

Inferred drug relations via UMLS 71 / NDF-RT 50 :


desloratadine
levocetirizine
levocetirizine dihydrochloride

Genetic Tests for Pollen Allergy

Anatomical Context for Pollen Allergy

Organs/tissues related to Pollen Allergy:

MalaCards : Skin, T Cells, B Cells, Lung, Monocytes, Eye, Neutrophil

Publications for Pollen Allergy

Articles related to Pollen Allergy:

(show top 50) (show all 1423)
# Title Authors PMID Year
1
Monitoring disease activity of pollen allergies: What crowdsourced data are telling us. 62
36438191 2022
2
Bacterial Species Associated with Highly Allergenic Plant Pollen Yield a High Level of Endotoxins and Induce Chemokine and Cytokine Release from Human A549 Cells. 62
35668156 2022
3
Risk assessment of pollen allergy in urban environments. 62
36473878 2022
4
Purification and characterization of enolase as a novel allergen in Platanus acerifolia pollen. 62
36252468 2022
5
Tubomanometry correlations with patient characteristics and other diagnostic tests of Eustachian tube dysfunction: a cohort study of 432 ears. 62
35381864 2022
6
Update about Oralair® as a treatment for grass pollen allergic rhinitis. 62
35704772 2022
7
The scenario of the studies on ragweed (Ambrosia Sp.) and related issues from its beginning to today: a useful tool for future goals in a one health approach. 62
36300205 2022
8
Identification of Allergenic Proteins in Velvet Mesquite (Prosopis velutina) Pollen: An Immunoproteomics Approach. 62
36143457 2022
9
Associations between outdoor air pollution, ambient temperature and fraction of exhaled nitric oxide (FeNO) in university students in northern China - A panel study. 62
35513063 2022
10
RNA sequencing of single allergen-specific memory B cells after grass pollen immunotherapy: Two unique cell fates and CD29 as a biomarker for treatment effect. 62
36153670 2022
11
Identification of prominent airborne pollen in a city situated in foot-hills of Himalayas, Chandigarh, India. 62
36173519 2022
12
Identification of allergens and allergen hydrolysates by proteomics and metabolomics: A comparative study of natural and enzymolytic bee pollen. 62
35840258 2022
13
Differential Quercus spp. pollen-particulate matter interaction is dependent on geographical areas. 62
35378190 2022
14
A new cysteine protease allergen from Ambrosia trifida pollen: proforms and mature forms. 62
35598503 2022
15
[Allergenic risk analysis of street trees of urban alleys in Qingyang District, Chengdu, China]. 62
35729140 2022
16
Isolation of nanobodies with potential to reduce patients' IgE binding to Bet v 1. 62
34837242 2022
17
Molecular diagnosis contribution for personalized medicine. 62
35174793 2022
18
Determining the minimal important differences in the RQLQ score with grass and tree allergy immunotherapy versus placebo in adults with moderate-to-severe allergy. 62
34986506 2022
19
Oak pollen allergy in Korea. 62
35748545 2022
20
Intralymphatic immunotherapy with one or two allergens renders similar clinical response in patients with allergic rhinitis due to birch and grass pollen. 62
35332591 2022
21
Pollen allergy: Developing multi-sectorial strategies for its prevention and control in lower and middle-income countries. 62
35334435 2022
22
Capsicum Allergy: Involvement of Cap a 7, a New Clinically Relevant Gibberellin-Regulated Protein Cross-Reactive With Cry j 7, the Gibberellin-Regulated Protein From Japanese Cedar Pollen. 62
35557497 2022
23
The association of timothy grass allergy and cat ownership on cat sensitization. 62
35524353 2022
24
Pre-seasonal immunotherapy is effective in both monosensitized and polysensitized patients with allergic rhinitis. 62
35448936 2022
25
Allergen immunotherapy in MASK-air users in real-life: Results of a Bayesian mixed-effects model. 62
35344295 2022
26
Pollen Allergy in a Changing Planetary Environment. 62
35255535 2022
27
Ex Vivo Immunomodulatory Effects of Lactobacillus-, Lacticaseibacillus-, and Bifidobacterium-Containing Synbiotics on Human Peripheral Blood Mononuclear Cells and Monocyte-Derived Dendritic Cells in the Context of Grass Pollen Allergy. 62
35113319 2022
28
5-grass-pollen SLIT effectiveness in seasonal allergic rhinitis: Impact of sensitization to subtropical grass pollen. 62
35280502 2022
29
Prevalence and Risk Factors for Allergic Rhinitis in China: A Systematic Review and Meta-Analysis. 62
36193147 2022
30
Online public attention toward allergic rhinitis in Wuhan, China: Infodemiology study using Baidu index and meteorological data. 62
36262246 2022
31
Evaluation of a Novel Adjuvanted Vaccine for Ultrashort Regimen Therapy of Artemisia Pollen-Induced Allergic Bronchial Asthma in a Mouse Model. 62
35371056 2022
32
Generation of high affinity ICAM-1-specific nanobodies and evaluation of their suitability for allergy treatment. 62
36439110 2022
33
The effect of face mask usage on the allergic rhinitis symptoms in patients with pollen allergy during the covid-19 pandemic. 62
34534761 2022
34
Serum IgE profiles in Chinese pollinosis patients with grass pollen sensitisation. 62
35079319 2022
35
Do we need aerobiological air monitoring in desert climates? The Qatar experience. 62
35909412 2022
36
Pollen Allergy Screening with Allergen-Specific and Total Immunoglobulin E Titers. 62
35359700 2022
37
Approximate or accurate? Efficacy of daily use of weather and air quality mobile applications for pollen allergy sufferers? 62
35080313 2022
38
Identification of Diagnostic Biomarkers of Rape Pollen Allergy Based on MRNA Sequencing. 62
36212976 2022
39
Tourist risk assessment of pollen allergy in tourism attractions: A case study in the Summer Palace, Beijing, China. 62
36339238 2022
40
Urban vs rural - Prevalence of self-reported allergies in various occupational and regional settings. 62
35145605 2022
41
Clinical Relevance of Profilin Sensitization Concerning Oral Allergy Syndrome in Birch Pollen Sensitized Patients. 62
35221697 2022
42
Predictors of Airway Hyperresponsiveness in Symptomatic Children with Normal Spirometry and Suspicious of Possible Asthma. 62
34903689 2022
43
Pollen Production of Selected Grass Species in Russia and India at the Levels of Anther, Flower and Inflorescence. 62
35161263 2022
44
The Allergen-Specific IgE Concentration Is Important for Optimal Histamine Release From Passively Sensitized Basophils. 62
35769579 2022
45
The Fusion Protein rFlaA:Betv1 Modulates DC Responses by a p38-MAPK and COX2-Dependent Secretion of PGE2 from Epithelial Cells. 62
34943923 2021
46
Are Markers of Allergic Inflammation in Grass Pollen Allergy Influenced by H1 Antihistamines? 62
35011854 2021
47
Safety of the standardized quality tree sublingual immunotherapy tablet: Pooled safety analysis of clinical trials. 62
33905129 2021
48
The "Stay at home" COVID-19 lockdown restriction may have prevented asthma exacerbations in children affected by pollen allergy: a single center experience. 62
34647702 2021
49
Isotretinoin-associated exercise-induced anaphylaxis in a patient with birch pollinosis and soybean sensitization: case presentation and literature review. 62
34627369 2021
50
Eosinophilic esophagitis induced by sublingual immunotherapy with cedar pollen: a case report. 62
34786374 2021

Variations for Pollen Allergy

Expression for Pollen Allergy

Search GEO for disease gene expression data for Pollen Allergy.

Pathways for Pollen Allergy

Pathways related to Pollen Allergy according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.26 IL5 IL4 IL13 IL10 CD4 CCR6
2
Show member pathways
11.98 IL5 IL4 IL10 CD4
3 11.83 PTGDR2 IL5 IL4 IL10 CD4
4 11.8 IL4 IL13 IL10
5 11.73 IL10 IL13 IL4 IL5
6 11.62 IL5 IL4 IL13
7 11.57 ICOSLG IL10 IL4
8 11.55 IL5 IL4 IL10
9 11.5 IL5 IL4 IL13
10
Show member pathways
11.48 IL5 IL4 IL13 IL10
11 11.46 IL5 IL4 IL10
12 11.22 IL5 IL4 IL13 IL10 CD4
13 11.16 IL5 IL4 IL13
14 11.07 PTGDR2 IL5 IL4 IL13 IL10 CD4
15 11.05 IL5 IL4 IL13 IL10
16 10.97 IL5 IL4 IL13 IL10
17 10.88 IL5 IL4 IL13 IL10 ALK
18 10.82 IL5 IL4 IL13 IL10 CD4
19 10.76 IL4 CD4
20 10.69 IL5 IL4 IL13

GO Terms for Pollen Allergy

Biological processes related to Pollen Allergy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.33 PTGDR2 PDCL IL5 IL4 IL13 IL10
2 negative regulation of inflammatory response GO:0050728 9.97 ENPP3 IL10 IL13 IL4
3 positive regulation of B cell proliferation GO:0030890 9.91 IL5 IL4 IL13
4 type 2 immune response GO:0042092 9.76 IL4 IL10
5 negative regulation of endothelial cell apoptotic process GO:2000352 9.73 IL4 IL13 IL10
6 regulation of isotype switching GO:0045191 9.62 IL4 IL10
7 negative regulation of complement-dependent cytotoxicity GO:1903660 9.46 IL4 IL13
8 immune response GO:0006955 9.44 PTGDR2 IL5 IL4 IL13 IL10 CD4
9 positive regulation of immunoglobulin production GO:0002639 9.43 IL5 IL13 IL10

Sources for Pollen Allergy

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....